Kolexia
Andre Fabrice Oncologie médicale
Andre Fabrice
Oncologie médicale
Gustave-Roussy
Villejuif, France
1.1 K Activités
15.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Tumeurs du poumon Carcinome pulmonaire non à petites cellules Fatigue COVID-19 Récidive tumorale locale Carcinomes

Collaborateurs

Voir plus
Soria Jean-Charles
Soria Jean-Charles
Gustave-Roussy, Villejuif, France
Delaloge Suzette
Delaloge Suzette
Gustave-Roussy, Villejuif, France
Campone Mario
Campone Mario
Ico - Site Paul Papin, Angers, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Novartis
16 collaboration(s)
Dernière en 2021
AstraZeneca
4 collaboration(s)
Dernière en 2023
Eisai
3 collaboration(s)
Dernière en 2020
Daiichi Sankyo
3 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Essai Clinique (Lilly)   18 mars 2024
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast cancer research : BCR   04 mars 2024
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Essai Clinique (Novartis)   26 février 2024
Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.
ESMO open   23 février 2024
Forget lung, breast or prostate cancer: why tumour naming needs to change.
Nature   15 février 2024
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
MONALEESA-7: A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Essai Clinique (Novartis)   13 février 2024
Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care.
ESMO open   12 février 2024
LESS: Single-arm Study to De-escalate Adjuvant Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk of Metastasis
Essai Clinique (Agendia)   02 février 2024
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.
JCO precision oncology   22 janvier 2024